REDHILL BIOPHAR/S (NASDAQ:RDHL) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a report issued on Thursday.
A number of other analysts also recently weighed in on RDHL. LADENBURG THALM/SH SH initiated coverage on shares of REDHILL BIOPHAR/S in a research report on Monday, June 25th. They issued a “buy” rating and a $20.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $36.00 target price on shares of REDHILL BIOPHAR/S in a research report on Monday, July 2nd. Finally, Zacks Investment Research downgraded shares of REDHILL BIOPHAR/S from a “buy” rating to a “hold” rating in a research report on Tuesday, September 4th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $20.80.
NASDAQ:RDHL opened at $7.99 on Thursday. The stock has a market capitalization of $187.84 million, a PE ratio of -3.07 and a beta of 0.74. REDHILL BIOPHAR/S has a 1-year low of $4.30 and a 1-year high of $11.49.
REDHILL BIOPHAR/S (NASDAQ:RDHL) last released its earnings results on Thursday, August 30th. The biotechnology company reported ($0.52) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.05). The business had revenue of $2.35 million during the quarter, compared to analysts’ expectations of $2.77 million. REDHILL BIOPHAR/S had a negative return on equity of 133.07% and a negative net margin of 564.71%. As a group, research analysts anticipate that REDHILL BIOPHAR/S will post -1.73 earnings per share for the current fiscal year.
An institutional investor recently raised its position in REDHILL BIOPHAR/S stock. 683 Capital Management LLC boosted its position in shares of REDHILL BIOPHAR/S (NASDAQ:RDHL) by 22.8% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 2,042,654 shares of the biotechnology company’s stock after purchasing an additional 378,751 shares during the quarter. REDHILL BIOPHAR/S comprises about 1.2% of 683 Capital Management LLC’s holdings, making the stock its 13th biggest holding. 683 Capital Management LLC owned 9.60% of REDHILL BIOPHAR/S worth $17,424,000 at the end of the most recent reporting period. 22.50% of the stock is currently owned by institutional investors and hedge funds.
REDHILL BIOPHAR/S Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases. It commercializes and promotes gastrointestinal products in the United States. The company's pipeline includes various drug candidates that are in advanced clinical development stages, including three Phase III-stage programs.
See Also: What Is An Exchange-Traded Fund (ETF)?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.